Compare Crispr Therapeutics AG (CRSP) vs Realty Income Corp (O) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Realty Income Corp — how do they compare? Crispr Therapeutics AG trades at $54.08 (market cap $5.17B), while Realty Income Corp trades at $62.05 (market cap $58.56B). The key difference: Realty Income Corp is far larger — about 11.3× Crispr Therapeutics AG's market cap, and Realty Income Corp pays a 5.25% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | O | |
|---|---|---|
Market Cap | $5.17B | $58.56B |
Sector | Health | Real Estate |
52-Week High | $76.78 | $67.56 |
52-Week Low | $44.34 | $55.93 |
Enterprise Value | $3.59B | $89.19B |
Dividend Yield | — | 5.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.52, up 3.64% in the last session, with a bullish technical outlook from moving averages but overbought RSI signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by Casgevy sales. Analyst consensus is a Buy with a $76 price target, reflecting optimism for pipeline catalysts.
The outlook is supported by strong product sales and clinical progress, but significant risks include persistent negative margins, high cash burn, and reliance on pipeline success. Investors face a high-risk, high-reward scenario with the stock trading near resistance levels amid volatile earnings history.
Realty Income (O) trades at $62.51, up 0.24% today, with a bearish technical signal from moving averages but bullish oscillators like RSI. The REIT reported Q2 2026 AFFO of $1.09 per share, matching estimates, and raised full-year guidance, supported by a 98.8% occupancy rate. Recent news highlights its high dividend yield and 115th consecutive quarterly increase, alongside a $6 billion data center joint venture announced in August 2026.
Outlook: Strong dividend growth and strategic expansion into data centers offer upside, but high P/E of 45.63 and recent EPS misses pose valuation risks. Analysts target $67.13 consensus, implying modest growth, with debt-to-asset ratio rising to 39.93% in 2025 signaling financial leverage concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →
